5AM Venture Management, LLC
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), 5AM Venture Management, LLC reported 20 stock positions worth $360.2 million. Its top holding was Erasca (ERAS) at 15.7% of the portfolio, followed by Entrada Therapeutics (TRDA, 14.2%) and Tyra Biosciences (TYRA, 10.9%). Compared with Q4 2025, it opened 1 new position, sold out of 2 and reduced 2. The biggest buy was a new position in Alx Oncology (ALXO) and the biggest sale an exit from Viridian Therapeutics (VRDN).
- Most Recent 13F
- Q2 2026
- Location
- SAN FRANCISCO, CA
- CIK
- 0001799883
- Portfolio Value
- $360.2M (Q1 2026)
- SEC Filing
- 0001799883-26-000002 ↗ filed May 15, 2026
Holdings Value
Holdings 20 stocks · $360.2M
| ERAS Erasca Inc. | 15.66% | 3,485,971 | $56.4M | Reduce -35.5% |
| TRDA Entrada Therapeutics Inc. | 14.21% | 4,056,379 | $51.2M | No change |
| TYRA Tyra Biosciences Inc. | 10.94% | 1,029,298 | $39.4M | No change |
| CAMP CAMP4 Therapeutics Corp. | 7.19% | 5,869,091 | $25.9M | No change |
| CNTA Centessa Pharmaceuticals Ltd. | 6.41% | 580,945 | $23.1M | No change |
| PHVS Pharvaris NV | 6.26% | 797,600 | $22.5M | No change |
| MPLT Maplight Therapeutics Inc. | 5.36% | 950,011 | $19.3M | No change |
| TECX Tectonic Therapeutic Inc. | 5.21% | 606,660 | $18.8M | No change |
| CLDX Celldex Therapeutics Inc. | 4.38% | 497,270 | $15.8M | No change |
| ARTV Artiva Biotherapeutics Inc. | 4.21% | 2,353,304 | $15.2M | No change |
| EYPT Eyepoint Inc. | 3.76% | 1,050,000 | $13.5M | No change |
| SRZN Surrozen Inc. | 3.13% | 387,500 | $11.3M | No change |
| ZNTL Zentalis Pharmaceuticals Inc. | 2.56% | 3,947,913 | $9.2M | No change |
| GHRS GH Research PLC | 2.24% | 572,665 | $8.1M | No change |
| TARA Protara Therapeutic Inc. | 1.98% | 1,369,782 | $7.1M | No change |
| BHVN Biohaven Ltd. | 1.74% | 738,972 | $6.3M | No change |
| ALXO Alx Oncology Holdings Inc. | 1.70% | 3,057,325 | $6.1M | New |
| SKYE Skye Bioscience Inc. | 1.65% | 9,681,763 | $6.0M | No change |
| RLYB Rallybio Corp. | 0.73% | 291,788 | $2.6M | Reduce -35.7% |
| SLN Silence Therapeutics PLC-ADR | 0.70% | 476,200 | $2.5M | No change |
Portfolio Sells Q4 2025 → Q1 2026
Portfolio Buys Q4 2025 → Q1 2026
| ALXO Alx Oncology Holdings Inc. | New | 1.70% | +1.70 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 16 | $287.9M | MPLT, TYRA, TRDA, PHVS, CAMP |
| Q1 2026 | 20 | $360.2M | ERAS, TRDA, TYRA, CAMP, CNTA |
| Q4 2025 | 21 | $318.1M | TRDA, CAMP, TYRA, VRDN, PHVS |
| Q3 2025 | 25 | $273.0M | SKYE, TRDA, PHVS, CAMP, CNTA |
| Q2 2025 | 29 | $260.1M | SKYE, TRDA, DNTH, ELVN, PHVS |
| Q1 2025 | 31 | $264.4M | TRDA, ELVN, DNTH, SKYE, PHVS |
| Q4 2024 | 31 | $419.1M | TRDA, ELVN, SKYE, TECX, ARTV |
| Q3 2024 | 28 | $484.0M | TRDA, ELVN, SKYE, ARTV, DNTH |
| Q2 2024 | 28 | $447.1M | SKYE, TRDA, ELVN, DNTH, CLDX |
| Q1 2024 | 26 | $446.6M | ELVN, TRDA, DNTH, MRUS, CLDX |